Drugs / Retagliptin
Retagliptin
Trials 18 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02815774 Comparator | Jun 2014 → Jan 2015 | impaired renal function disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02815787 Comparator | Mar → Jul 2014 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02815722 Comparator | Jul 2013 → May 2014 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02815657 Comparator | Apr 2013 → Jan 2014 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Retagliptin | “Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients” NCT06417489 ↗ |
| Known as | Retagliptin phosphate | “Retagliptin phosphate tablet is a DPP IV inhibitor durg” NCT05054842 ↗ |
| Known as | SP2086 | “The purpose of this study is to assess the effect of food on the single-dose PK of SHR3824, SP2086 and metformin in the HR20031 FDC tablets in healthy subjects.” NCT05692934 ↗17“Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout” NCT05682495 ↗ |
| Action | Inhibit | “SP2086 is a new dipeptidyl peptidase(DPP)-4 inhibitor.” NCT01969318 ↗ |
| Modality | Small molecule | — CHEMBL4297435 ↗ |
| Route | Oral | “SP2086 will be administered orally (by mouth) as 100mg” NCT02500485 ↗ |